Non-small cell lung cancer metastatic
Not recruitingStudy Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Inhibitor Treatment
Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Inhibitor Treatment
- Disease:Non-small cell lung cancer metastatic
- Substances:DocetaxelHumanised IgG1 monoclonal antibody against CD152
Spain- Participants:18–64 years · 65+ years
- Substances:Docetaxel
- Sponsor:Oncoc4 Inc.





